Zimmer Biomet Holdings ZBH Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 282.2%-3.8pp | 283.3%-3.7pp | 285%-2.3pp | 285.4%-1.8pp | 286.1%-1.0pp | |
| Operating margin | 60.1%-6.6pp | 63.1%-2.9pp | 66.5%0.0pp | 66.4%+3.6pp | 66.7%+7.9pp | |
| Net margin | 38.2%-13.0pp | 41%-11.2pp | 44.2%-10.1pp | 48.4%— | 51.2%— | |
| Returns | ||||||
| Return on equity | 24.6%-6.6pp | 25.8%-5.8pp | 27.5%-5.3pp | 29.8%— | 31.2%— | |
| Return on invested capital | 23.2%-3.1pp | 23.3%-3.5pp | 23.7%-4.1pp | 25.1%-1.1pp | 26.3%+2.0pp | |
| Efficiency | ||||||
| Asset turnover | 1.5×0.0× | 1.4×0.0× | 1.4×0.0× | 1.4×0.0× | 1.4×0.0× | |
| Liquidity | ||||||
| Current ratio | 8×+1.0× | 8.7×+2.5× | 8.6×+2.7× | 7.6×+0.9× | 7×-0.4× | |
| Leverage | ||||||
| Debt-to-equity | 2.4×+0.4× | 2.4×+0.5× | 2.3×+0.4× | 2.2×+0.4× | 2.1×+0.2× | |
| Net debt / EBITDA | 12.2×+2.0× | 11.6×+1.5× | 11×+0.9× | 10.8×+0.5× | 10.2×-0.5× | |
| Per Share | ||||||
| Book value per share | $255.96+4.1% | $253.30+3.4% | $250.55+3.0% | $247.34+2.2% | $245.91+2.8% | |
| Valuation | ||||||
| Market capitalization | $73.29B-16.7% | $78.13B-16.0% | $81.34B-16.5% | $84.03B-14.9% | $88.03B-17.8% | |
| Price / earnings | 94.9×+4.2× | 96.4×+1.7× | 94.4×-1.8× | 90.6×— | 90.8×— | |
| Price / sales | 9×-2.5× | 9.9×-2.5× | 10.4×-2.6× | 10.9×-2.4× | 11.5×-3.1× | |
| Price / book | 5.8×-1.3× | 6.2×-1.2× | 6.5×-1.3× | 6.8×-1.1× | 7×-1.5× | |
| EV / EBITDA | 44.1×-5.1× | 45.5×-6.6× | 45.9×-8.3× | 47.6×-9.4× | 49.2×-14.9× | |
| Dividend yield | 4.2%+0.6pp | 4%+0.5pp | 3.8%+0.5pp | 3.7%+0.5pp | 3.6%+0.6pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Zimmer Biomet Holdings's profit margins?
- Zimmer Biomet Holdings (ZBH) runs a 70.0% gross margin and a 14.0% operating margin, with a 9.1% net margin.
- Where do Zimmer Biomet Holdings's ratios come from?
- Every ratio is computed from Zimmer Biomet Holdings's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
